Supernus Pharmaceuticals (SUPN) Capital Expenditures Growth (5y) (2016 - 2025)
Supernus Pharmaceuticals (SUPN) Capital Expenditures Growth (5y) (2016 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.51 Bn | 87.64 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.21 Bn | 1.97 Bn |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - |
| 7 | Viatris | 20.25 Bn | 18.44 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.48 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.36 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14.71% |
| Sep 30, 2025 | -4.45% |
| Mar 31, 2025 | -33.62% |
| Dec 31, 2024 | -39.35% |
| Sep 30, 2024 | 31.44% |
| Jun 30, 2024 | 5.49% |
| Mar 31, 2024 | 4.82% |
| Dec 31, 2023 | -18.89% |
| Sep 30, 2023 | -18.06% |
| Jun 30, 2023 | 12.31% |
| Mar 31, 2023 | 1.90% |
| Dec 31, 2022 | -17.32% |
| Jun 30, 2022 | -43.78% |
| Mar 31, 2022 | 12.85% |
| Dec 31, 2020 | -24.28% |
| Sep 30, 2020 | -18.94% |
| Mar 31, 2020 | 68.10% |
| Dec 31, 2019 | 85.55% |
| Sep 30, 2019 | -25.44% |
| Jun 30, 2019 | -16.12% |